Navigation Links
Existing drugs may help more breast cancer patients
Date:12/7/2012

More patients can benefit from highly effective breast cancer drugs that are already available, according to DNA sequencing studies by researchers at Washington University School of Medicine in St. Louis and other institutions.

The investigators found that some women with the HER2 negative subtype may benefit from anti-HER2 drugs even though standard tests don't indicate they are candidates for the drugs.

"These patients are going to be missed by our routine testing for HER2 positive breast cancer," says Ron Bose, MD, PhD, assistant professor of medicine. "Currently they're not going to receive a HER2 targeted drug because we don't have a way to identify them. And we predict they are going to have a more aggressive form of breast cancer."

Bose, who treats patients at Washington University's Siteman Cancer Center at Barnes-Jewish Hospital, will present the data Dec. 7 at the San Antonio Breast Cancer Symposium.

Today, a type of breast cancer known as HER2 positive is treated with drugs that inhibit the function of the HER2 protein. To be classified as HER2 positive, a patient must have more than the normal two copies of the HER2 gene. Too much HER2 drives tumor growth and some HER2 positive patients may have as many as 20 copies of the gene. Doctors test for this gene "amplification" in every patient diagnosed with breast cancer. It must be present for a woman to receive anti-HER2 drugs.

But instead of multiple copies of the gene churning out too much HER2, some patients deemed HER2 negative based on standard testing may have mistakes in just a few "letters" of the DNA in their two gene copies that result in excess activity of the protein. Bose and his colleagues estimate that these undetected HER2 mutations rather than the HER2 amplification -- may be driving tumor growth in 1.5 to 2 percent of all breast cancer patients. With about 230,000 new cases of breast cancer diagnosed in the United States each year, eve
'/>"/>

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
2. Existing drugs offer new treatment options for high-risk childhood leukemia subtype
3. Mahvrick Expands to Brazil, Russia, India, China to Support Existing Client Customer Growth
4. Zane Benefits Publishes Information About Over-the-Counter (OTC) Medicines, Drugs and HRAs
5. Heart Failure Drugs Put to the Test
6. More New Drugs a Bad Fit With Grapefruit, Study Finds
7. Continued Use of ADHD Drugs May Reduce Criminal Behavior, Study Says
8. UAlberta prostate cancer researcher and team developing homing beacon drugs to target cancer cells
9. Can breast cancer cells reaction to cancer drugs be predicted?
10. Quick, high-volume test offers fast track in search for Alzheimers drugs
11. Structure of enzyme unravelled providing basis for more accurate design of chemotherapeutic drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Existing drugs may help more breast cancer patients
(Date:7/14/2014)... Texas (PRWEB) July 14, 2014 The ... encourage investment in the Global Mobile Health Solutions market. ... in the Health IT for Economic and Clinical Health ... February 2009. , Analysts forecast the Global Mobile ... of 34.88 percent over the period 2013-2018. According to ...
(Date:7/14/2014)... The report “Intelligent Building Automation Technologies ... Safety, Facility Management], IT Technologies & Industry Verticals ... - 2019)” defines and segments the IBAS market ... forecasting of revenues. The report also identifies the ... impacting it, along with the technology roadmap and ...
(Date:7/14/2014)... Physical fitness may buffer some of the adverse health ... study by researchers from the American Cancer Society, The ... appears in the journal Mayo Clinic Proceeding s, ... obesity and blood markers associated with cardiovascular disease is ... Sedentary behavior has been linked to an increase risk ...
(Date:7/14/2014)... TX (PRWEB) July 14, 2014 ... heart valves market in Americas. The analysis includes ... the 2007–2020 period and key company share data ... US, Canada, Brazil and Mexico. It uses data ... secondary research and in-house analysis. , Scope, ...
(Date:7/14/2014)... Secure Decisions, a leading provider of ... the Software Assurance Marketplace (SWAMP) to build a powerful ... drives everyday life. , The SWAMP, implemented by a ... Morgridge Institute for Research, is funded by the Department ... practices by building a free facility with a diverse ...
Breaking Medicine News(10 mins):Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 2Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 3Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 4Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3
... made him the last of his line, researchers say ... powerful Habsburg royal family ruled Spain for centuries until the ... , Now, a new study suggests the reason for their ... and their unfortunate habit of marrying their own relatives. ...
... the highest level of excellence, achieving ASQ CQI Certifications. , ... ... Board of the American Society for Quality is pleased to announce ... completed the requirements to be named an ASQ-Certified Quality Inspector (ASQ ...
... 8 Saints Mary and Elizabeth Medical Center, 2233 ... Blue Cross and Blue Shield of Illinois, Childhood Health ... for children at risk for obesity and diabetes. This ... Obesity is an epidemic in the United States. Since ...
... 8 This Sunday, individuals all over the ... the women who gave them life: their mothers. While people ... the International Breast Milk Project (IBMP) hopes to inspire some ... organization that helps mothers in the United States send their ...
... Protect Patients and Consumers ROCKVILLE, Md., May 8 ... substantial increase in funding for the Food and ... budget. Following the Obama administration,s voiced support for ... increase the agency,s ability to protect American patients ...
... May 8 PRO-DEX, INC. (Nasdaq: PDEX ) ... of the Company,s fiscal 2009 third quarter financial results. The ... on Thursday, May 14, 2009 at 4:30 p.m. Eastern Time ... Company,s website at www.pro-dex.com . Mark ...
Cached Medicine News:Health News:Inbreeding May Have Doomed Spain's Habsburg Dynasty 2Health News:Inbreeding May Have Doomed Spain's Habsburg Dynasty 3Health News:Clinical Instrument Repair Consultants Receive ASQ-Certified Quality Inspector 2Health News:Blue Cross and Blue Shield Funds Diabetes Education at Saints Mary and Elizabeth Medical Center 2Health News:International Breast Milk Project Helps Mothers Worldwide 2Health News:USP Applauds President's Budget Support for FDA 2Health News:Pro-Dex, Inc. Announces Fiscal 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:7/14/2014)... 14, 2014  Mylan Inc. (NASDAQ: MYL ) ... with Abbott (NYSE: ABT ... non-U.S. developed markets specialty and branded generics business ("the Assets") ... will receive 105 million shares of the combined company ... $50.20 on Friday, July 11, 2014, representing an approximately 21% ...
(Date:7/13/2014)... July 13, 2014  Eli Lilly and Company ... from its non-clinical study in genetically engineered mice ... the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE ... more effective in removing clumps of amyloid-beta protein ... thought to lead to Alzheimer,s disease (AD) – ...
(Date:7/11/2014)... , July 11, 2014 The consumer ... evolving across industry sectors to better identify winning ... ways to engage with and understand consumers, as ... and make critical purchasing decisions. ... Practices, LLC, one area where organizations can observe ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2